Search
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Tegoprazan
go.drugbank.com/drugs/DB16690Investigational[A234220] It has also been observed to be efficacious independent of food intake.[A234220] … Tegoprazan (also known as CJ-12420) is a novel therapeutic developed by CJ Healthcare Corp for treating acid-related gastrointestinal diseases.
Urelumab
go.drugbank.com/drugs/DB12077InvestigationalThe antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb- derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with … Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma.
Zinc citrate
go.drugbank.com/drugs/DB11154ApprovedInvestigationalIt is available as dietary supplements as a treatment of zinc deficiency and source of zinc, which is an essential trace element.
CLX-0921
go.drugbank.com/drugs/DB05854ExperimentalCLX-0921 has a spectrum of activity that differs from commercially available thiazolidinediones. This substance targets the protein peroxisome proliferator-activated receptor gamma.
Deserpidine
go.drugbank.com/drugs/DB01089ApprovedWithdrawnDeserpidine is an ester alkaloid drug isolated from Rauwolfia canescens (family Apocynaceae) with antipsychotic and antihypertensive properties that has been used for the control of high blood pressure
Imiglucerase
go.drugbank.com/drugs/DB00053ApprovedInvestigationalHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. Alglucerase is prepared by modification of the oligosaccharide chains of human ...
E-2012
go.drugbank.com/drugs/DB05171ExperimentalE-2012 is a gamma secretase modulator that is being evaluated as a potential new treatment for Alzheimer's disease.
Alemtuzumab
go.drugbank.com/drugs/DB00087ApprovedInvestigational[L43397] Alemtuzumab was approved by the FDA in 2001.[L43397] It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL).
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigational[L47122] Rozanolixizumab was also approved by the European Commission on January 5, 2024.[L50973] … [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November